TP53 mutations in NSCLC (~50%) — adverse prognostic; modulate ICI response (TP53+KRAS may...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-TP53-MUT-NSCLC |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-NSCLC |
| Sources | SRC-CIVIC SRC-NCCN-NSCLC-2025 |
Actionability Facts
| Biomarker | BIO-TP53-MUTATION |
|---|---|
| Variant | any pathogenic mutation OR del(17p) |
| Disease | DIS-NSCLC |
| ESCAT tier | IIIB |
| Recommended combinations | per usual NSCLC algorithm based on driver |
| Evidence summary | TP53 mutations in NSCLC (~50%) — adverse prognostic; modulate ICI response (TP53+KRAS may have higher TMB/ORR; TP53+EGFR may have shorter OS). Not directly targeted. |
Notes
ESCAT IIIB. Gene-level cell — biallelic vs monoallelic distinction matters in MDS/AML (biallelic = TP53-multihit per IPSS-M / ICC 2022, far worse). Per-hotspot cells provided for the most common variants.
Used By
No reverse references found in the YAML corpus.